Serum phospholipid alterations and their control by chlorophenoxyisobutyrate and betabenzalbutyrate in puromycin aminonucleoside induced nephrotic syndrome in the rat.
D000818:Animals; D000924:Anticholesteremic Agents / Q000494:pharmacology*; D002087:Butyrates / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood; D002792:Cholestyramine Resin / Q000494:pharmacology; D002994:Clofibrate / Q000494:pharmacology; D005260:Female; D008074:Lipoproteins / Q000097:blood; D009404:Nephrotic Syndrome / Q000097:blood* / Q000139:chemically induced; D010713:Phosphatidylcholines / Q000097:blood; D010743:Phospholipids / Q000097:blood*; D011422:Propionates / Q000494:pharmacology*; D011691:Puromycin; D051381:Rats; D012709:Serum Albumin; D014280:Triglycerides / Q000097:blood
D000924:Anticholesteremic Agents; D002087:Butyrates; D008074:Lipoproteins; D010713:Phosphatidylcholines; D010743:Phospholipids; D011422:Propionates; D012709:Serum Albumin; D014280:Triglycerides; D002792:Cholestyramine Resin; D011691:Puromycin; D002784:Cholesterol; D002994:Clofibrate